You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Skip to content

This site is a non-promotional medical portal for Kenya Healthcare Professionals. Not a healthcare professional? Visit our Public site

GSK Logo
Search

Report adverse event

GSK Logo

For Kenya Healthcare Professionals

  • GSK Medical
  • Therapy Areas
    • Vaccines
    • Respiratory
  • Contact us
Oncology
  • GSK at Conferences
  • Congress Presentations
  • Pipeline
  • Resources
    • Resource Links
    • Patient Empowerment Alliance
  • Explore Our Science
    • Unmet Need in Oncology
      • Multiple Myeloma
      • Myelofibrosis
    • Mechanism of Disease
    • Disease Information
    • Mechanism of Disease
    • Educational Webinars
    • Educational Webinars (*Stand Alone*)
    • Educational Webinars
    • Stand Alone Webinar Page
  • GSK at Conferences
  • Congress Presentations
  • Pipeline
  • Resources
    • Resource Links
    • Patient Empowerment Alliance
  • Explore Our Science
    • Unmet Need in Oncology
      • Multiple Myeloma
      • Myelofibrosis
    • Mechanism of Disease
    • Disease Information
    • Mechanism of Disease
    • Educational Webinars
    • Educational Webinars (*Stand Alone*)
    • Educational Webinars
    • Stand Alone Webinar Page

Menu

  1. GSK Medical>
  2. Oncology>
  3. Explore Our Science>
  4. Educational Webinars (*Stand Alone*)

Educational Webinars-Standalone Page

This multimedia content is made available for HCPs specializing in oncology for learning and information purposes only to address the need of the medical community to better understand investigational interventions and the physiology of disease

View Educational Webinars from GSK oncology

Multiple Myeloma Conversations Webinar on BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma

Learn about ways to maximize efficacy, moderate adverse events, and improve the patient experience when using novel BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

European Hematology Association (EHA) 2023 Symposium on Addressing the Challenges of Anaemia and Thrombocytopenia in Myelofibrosis

Learn more about the significant burden of anemia and thrombocytopenia on patients and the current and emerging treatment options in MF in addition to case presentations followed by an expert panel discussion.

Myeloproliferative Neoplasms Controversies and Debates (MPN Co & D) 2023 Symposium on Raising the Bar in Cytopenic Myelofibrosis

Learn more about the implications and medical needs associated with anaemia and thrombocytopenia in patients with myelofibrosis, and the associated available and emerging agents, in addition to patient case presentations and an expert panel discussion.

Controversies in Multiple Myeloma (COMy) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma

Learn more about the changing treatment landscape associated with multiple myeloma, and novel BCMA-based combination regimens in early RRMM. This webinar/symposium was originally delivered on May 11, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

European Hematology Association (EHA) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma

Learn more about novel BCMA-based combination regimens in early RRMM, and real-world practical approaches to improving the benefit-risk profile with BCMA-targeted agents in earlier lines of therapy. This webinar/symposium was originally delivered on June 8, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Multiple Myeloma Conversations Webinar on Real World Evidence for the use of BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma

Learn more about emerging real-world evidence data for BCMA-targeted agents and practical considerations for selection of BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on April 24, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Multiple Myeloma Conversations Webinar on the Latest anti-BCMA Therapy Data from ASCO & EHA 2023

Learn more about recent BCMA-targeted monotherapy datasets presented at ASCO & EHA 2023, including DREAMM-3. This webinar/symposium was originally delivered on July 13, 2023, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Multiple Myeloma Conversations Webinar on Novel MOAs in Relapsed Refractory Multiple Myeloma

Learn about the clinical impact of re-treating with the same therapy class in RRMM, as well as, BCMA-targeting agents with novel MOAs as an alternative to re-treatment in RRMM. This webinar/symposium was originally delivered on September 14, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Controversies in Multiple Myeloma (COMy) 2022 Symposia on Unlocking the Potential of Novel BCMA combinations

Learn about the changing multiple myeloma therapeutic landscape, and the potential of novel BCMA combinations in multiple myeloma. This webinar/symposium was originally delivered on May 13, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

European Hematology Association 2022 on Potential Novel Combination Treatment in Multiple Myeloma

Learn about the dynamic landscape in multiple myeloma, integration of BCMA-targeted agents in early relapsed refractory multiple myeloma, and optimizing the benefit-risk profile and feasibility of sequencing of BCMA-targeted agents. This webinar/symposium was originally delivered on June 9, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Multiple Myeloma Conversations Webinar on Understanding Real-World Evidence in Triple-Class Relapsed Refractory Multiple Myeloma

Learn about the changing multiple myeloma therapeutic landscape, the importance of real-world evidence, and emerging real-world datasets for agents recently approved for the treatment of triple-class exposed/refractory multiple myeloma. This webinar/symposium was originally delivered on April 20, 2022, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

MOMENTUM: A Study of Momelotinib vs Danazol in Patients With Symptomatic and Anemic Myelofibrosis

Learn more about the phase 3 MOMENTUM study of momelotinib vs danazol in patients with symptomatic and anemic myelofibrosis, including the results at 24 weeks

International Myeloma Society (IMS) 2023 Symposium on the Management of the Aging Population in Multiple Myeloma

Learn more about the impact of aging population on the incidence and treatment of multiple myeloma. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.

Individualised Strategies to Optimize First-Line Maintenance Therapy in Advanced Ovarian Cancer

Learn about recent progress in first-line maintenance therapy for Ovarian Cancer

ESGO 2023 Niraparib OC Symposium Recording

ESGO 2023 Niraparib OC Symposium Recording

ESMO 2022 Ovarian Cancer symposium

AVANT-GARDE: Reframing the art of first-line maintenance therapy to optimize long-term outcomes in advanced ovarian cancer

ESMO 2022 Dr Lorusso highlights interview

ESMO 2022 highlights: An interview with Dr. Domenica Lorusso

ESMO 2022 Dr Gourley Highlights Interview

ESMO 2022 highlights: An interview with Professor Charlie Gourley

ESGO 2022 Symposium

Conversations and Controversies in First-Line Maintenance Therapy for Advanced Ovarian Cancer

SE-GBL-ON-WCNT-200001 | November 2023

Get in touch

 

Contact us

  • Report adverse event
  • Sitemap
  • Terms of use
  • Privacy Notice

©2024 GSK group of companies or its licensor. GlaxoSmithKline Export Limited, at 79 New Oxford Street, London, WC1A 1DG, UK.